Literature DB >> 25403863

Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.

Maren Carbon1, Christoph U Correll1.   

Abstract

Since currently available antipsychotic medications predominantly treat hallucinations, delusions, disorganized thoughts and behavior, and related agitation/aggression, attention has traditionally been focused on managing positive symptoms. However, prominent negative symptoms and clinically relevant cognitive impairment affect approximately 40% and 80% of people with schizophrenia, respectively. Moreover, negative and cognitive symptoms are closely related to functional outcomes, and contribute substantially to the overall illness burden. Therefore, approaches to describe, measure, and manage these symptom domains are relevant. This article summarizes the phenomenology, prevalence, assessment, and treatment of negative and cognitive symptoms in patients with schizophrenia, including pharmacologic and nonpharmacologic management strategies that can be used in clinical care now, as well as pharmacologic approaches that are being tested. Currently, no approved treatments targeting negative or cognitive symptomatology in schizophrenia are available. It is hoped that progress in the understanding of the neurobiology of these important symptom domains of schizophrenia will help develop effective treatment strategies in the future. However, until this goal is achieved, clinicians should avoid therapeutic nihilism. Rather, the severity and impact of negative and cognitive symptoms should be determined, quantified, and monitored. Further, psychosocial treatments have shown therapeutic benefits. Thus, cognitive behavioral therapy, cognitive remediation, social skills training, and computer-assisted training programs should be offered in conjunction with antipsychotic treatment. Several non-antipsychotic augmentation strategies can be tried off-label. Treatment plans that incorporate currently available management options for negative and cognitive symptomatology in patients with schizophrenia should be adapted over time and based on the individual's needs, with the aim to enhance overall outcomes.

Entities:  

Keywords:  Assessment; cognition; negative symptoms; schizophrenia; treatment

Mesh:

Substances:

Year:  2014        PMID: 25403863     DOI: 10.1017/S1092852914000601

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  47 in total

Review 1.  Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning.

Authors:  Koichi Kaneko
Journal:  Yonago Acta Med       Date:  2018-06-18       Impact factor: 1.641

2.  Cognitive Effects of High-Frequency rTMS in Schizophrenia Patients With Predominant Negative Symptoms: Results From a Multicenter Randomized Sham-Controlled Trial.

Authors:  Alkomiet Hasan; Birgit Guse; Joachim Cordes; Wolfgang Wölwer; Georg Winterer; Wolfgang Gaebel; Berthold Langguth; Michael Landgrebe; Peter Eichhammer; Elmar Frank; Göran Hajak; Christian Ohmann; Pablo E Verde; Marcella Rietschel; Raees Ahmed; William G Honer; Berend Malchow; Susanne Karch; Thomas Schneider-Axmann; Peter Falkai; Thomas Wobrock
Journal:  Schizophr Bull       Date:  2015-10-03       Impact factor: 9.306

Review 3.  Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia.

Authors:  Cassandra J Hatzipantelis; Monica Langiu; Teresa H Vandekolk; Tracie L Pierce; Jess Nithianantharajah; Gregory D Stewart; Christopher J Langmead
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-28

Review 4.  Fatty acid and vitamin interventions in adults with schizophrenia: a systematic review of the current evidence.

Authors:  Siok Ching Chia; Jeyakumar Henry; Yee Ming Mok; William G Honer; Kang Sim
Journal:  J Neural Transm (Vienna)       Date:  2015-09-09       Impact factor: 3.575

Review 5.  [Pharmacotherapy of schizophrenia].

Authors:  C U Correll
Journal:  Nervenarzt       Date:  2020-01       Impact factor: 1.214

6.  Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial.

Authors:  Paola Bozzatello; Silvio Bellino; Irene Mancini; Luisa Sandei; Enrico Zanalda; Paola Rocca
Journal:  Clin Drug Investig       Date:  2019-02       Impact factor: 2.859

7.  Effectiveness of Prescription-Based CNS Stimulants on Hospitalization in Patients With Schizophrenia: A Nation-Wide Register Study.

Authors:  Christopher Rohde; Christoffer Polcwiartek; Marton Asztalos; Jimmi Nielsen
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

8.  Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia.

Authors:  Hans-Gert Bernstein; Susan Müller; Hendrik Dobrowolny; Carmen Wolke; Uwe Lendeckel; Alicja Bukowska; Gerburg Keilhoff; Axel Becker; Kurt Trübner; Johann Steiner; Bernhard Bogerts
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-12-29       Impact factor: 5.270

Review 9.  Modeling synaptogenesis in schizophrenia and autism using human iPSC derived neurons.

Authors:  Christa W Habela; Hongjun Song; Guo-Li Ming
Journal:  Mol Cell Neurosci       Date:  2015-12-02       Impact factor: 4.314

Review 10.  Repetitive Noninvasive Brain Stimulation to Modulate Cognitive Functions in Schizophrenia: A Systematic Review of Primary and Secondary Outcomes.

Authors:  Alkomiet Hasan; Wolfgang Strube; Ulrich Palm; Thomas Wobrock
Journal:  Schizophr Bull       Date:  2016-07       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.